Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 4/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PPIB | P23284 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176810 | 0.73 | METAP1 (0.53) | ACHEMETAP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL2351080 | 0.73 | METAP1 (0.53) | ACHEMETAP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL992002 | 0.73 | ACHE (0.56) | ACHEMETAP1ALDH1A1CYP19A1CYP3A4 | |
| SCHEMBL30715530 | 0.73 | ACHE (0.56) | ACHEMETAP1ALDH1A1CYP19A1CYP3A4 | |
| SCHEMBL2175443 | 0.72 | PDE3B (0.50) | ACHEMETAP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL19737862 | 0.72 | METAP1 (0.51) | ACHEMETAP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL227930 | 0.71 | METAP1 (0.47) | ACHEMETAP1ALDH1A1CYP19A1CA1 | |
| SCHEMBL3860892 | 0.70 | ACHE (1.00) | ACHEMETAP1CYP19A1 | |
| SCHEMBL29894949 | 0.70 | ACHE (1.00) | ACHEMETAP1CYP19A1 | |
| SCHEMBL7505165 | 0.70 | HPGD (0.60) | ACHEMETAP1PDE3BPDE3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | ACHE 11/4885METAP1 388/4885PDE3B 427/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | ACHE 11/4885METAP1 388/4885PDE3B 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.